Guest: J. Eugene Huffstutter, MD <br>


  <p>With multiple FDA-approved biologics available for patients with psoriatic arthritis, how do we decide which option is best for each patient? Rheumatologist Dr. Joseph Huffstutter details what biologic therapies we have to choose from and the rationale for choosing one over another.</p>

Guest: J. Eugene Huffstutter, MD With multiple FDA-approved biologics available for patients with psoriatic arthritis, how do we decide which option is best for each patient? Rheumatologist Dr. Joseph Huffstutter details what biologic therapies we have to choose from and the rationale for choosing one over another.

Comparing Biologic Therapies for PsA: Rationales, Benefits, & Risks

Occurring in 20-30% of patients with psoriasis, PsA causes painful joint stiffness and swelling, often becoming worse over time. Currently, there is no known cure for PsA.
Beyond Skin Deep: Impacts of Psoriatic Arthritis takes an in-depth look at PsA, exploring the care continuum from disease recognition to diagnosis to treatment.
This non-certified educational series is sponsored by Lilly. Content for this series is produced and controlled by ReachMD. This series is intended for healthcare professionals only. 
 Sponsored by

Medicine

Occurring in 20-30% of patients with psoriasis, PsA causes painful joint stiffness and swelling, often becoming worse over time. Currently, there is no known cure for PsA. Beyond Skin Deep: Impacts of Psoriatic Arthritis takes an in-depth look at PsA, exploring the care continuum from disease recognition to diagnosis to treatment. This non-certified educational series is sponsored by Lilly. Content for this series is produced and controlled by ReachMD. This series is intended for healthcare professionals only. Sponsored by

Occurring in 20-30% of patients with psoriasis, PsA causes painful joint stiffness and swelling, often becoming worse over time. Currently, there is no known cure for PsA.
Beyond Skin Deep: Impacts of Psoriatic Arthritis takes an in-depth look at PsA, exploring the care continuum from disease recognition to diagnosis to treatment.
This non-certified educational series is sponsored by Lilly. Content for this series is produced and controlled by ReachMD. This series is intended for healthcare professionals only. 
&nbsp;Sponsored by

Share Comparing Biologic Therapies for PsA: Rationales, Benefits, & Risks

Sign up to save your podcasts

Comparing Biologic Therapies for PsA: Rationales, Benefits, & Risks

Comparing Biologic Therapies for PsA: Rationales, Benefits, & Risks